ChemoCentryx Profit Margin

The latest profit margin for CCXI is -270.12% as of March 2026. That compares with -497.09% in the prior-year period — up 45.7% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside ChemoCentryx's historical trend and sector peers before judging valuation or financial health.

Over the past year, CCXI's profit margin moved from -497.09% to -270.12% — a 45.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ChemoCentryx's valuation or profitability profile.

Against Healthcare companies, CCXI currently prints -270.12% for profit margin, while the sector average sits near 15.58%. That is roughly 1833.3% below the sector mean. Large gaps often invite a closer look at ChemoCentryx's growth, margins, and balance sheet.

Profit Margin shows how effectively ChemoCentryx converts resources into returns. At -270.12%, CCXI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -497.09% in the prior-year period — up 45.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CCXI's profit margin (-270.12%), review year-over-year change from -497.09%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.